Thrivent Financial for Lutherans
AGRX

Thrivent Financial for Lutherans’s Agile Therapeutics AGRX Stock Holding History

Thrivent Financial for Lutherans’s Portfolio AGRX Stock Details AGRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-36
Closed -$206K – 2576
2020
Q4 		$206K Sell
36
-9
-20% -$53K ﹤0.01% 2403
2020
Q3 		$274K Sell
45
-10
-18% -$57.3K ﹤0.01% 2214
2020
Q2 		$304K Hold
55
– – ﹤0.01% 2113
2020
Q1 		$203K Buy
+55
New +$316K ﹤0.01% 2119

Other funds holding AGRX

PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
IA
Investor AB Stockholm, Sweden $14.4B AUM 4.07% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
NIM
Needham Investment Management New York $3.33B AUM 163.16% 1-Year Est. Return
FMBTD
First Midwest Bank Trust Division Joliet, Illinois $777M AUM 29.48% 1-Year Est. Return

Thrivent Financial for Lutherans's AGRX Position: Q1 2021 in Review

Thrivent Financial for Lutherans sold out of Agile Therapeutics (AGRX) in Q1 2021, closing a stake of 36 shares — an estimated $206K sold.

Thrivent Financial for Lutherans first reported a position in AGRX in Q1 2020 and held it in 4 quarters. The position peaked at $304K in Q2 2020. 73 funds tracked by Wall St. Rank hold AGRX as of Q1 2021.

  • Thrivent Financial for Lutherans reported no remaining Agile Therapeutics position as of Q1 2021 after selling out during the quarter.
  • Thrivent Financial for Lutherans sold 36 Agile Therapeutics shares in Q1 2021, an estimated $206K.
  • Thrivent Financial for Lutherans first reported a position in Agile Therapeutics in Q1 2020 and held it in 4 quarters.
  • Thrivent Financial for Lutherans's Agile Therapeutics position peaked at $304K in Q2 2020.
  • 73 funds tracked by Wall St. Rank held Agile Therapeutics as of Q1 2021.

Based on Thrivent Financial for Lutherans's 13F filing for Q1 2021, filed 17 May 2021.